|
KMID : 1134120130160010012
|
|
Journal of Breast Cancer
2013 Volume.16 No. 1 p.12 ~ p.15
|
|
|
Eribulin for Advanced Breast Cancer: A Drug Evaluation
|
|
Shablak Alaaeldin
|
|
|
Abstract
|
|
|
|
Eribulin is a synthetic microtubule dynamics inhibitor that was developed from a marine natural product halichondrin B. It exhibited in vitro and in vivo activities against a wide number of malignancies. A number of advanced phase trials showed improved survival following eribulin treatment in pretreated advanced breast cancer patients. This review provides an overview of the background to the therapeutic use of eribulin in oncology, including its pharmacology, pharmacokinetics, clinical efficacy, safety, and potential economic factors.
|
|
|
KEYWORD
|
|
|
Breast neoplasms, Eribulin, Microtubule inhibitor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|